Quantitative Mass Spectrometric Immunoassays for Population Proteomics

Award Information
Agency: Department of Health and Human Services
Branch: N/A
Contract: 1R43RR025701-01A1
Agency Tracking Number: RR025701
Amount: $197,319.00
Phase: Phase I
Program: SBIR
Awards Year: 2009
Solicitation Year: 2009
Solicitation Topic Code: N/A
Solicitation Number: PHS2009-2
Small Business Information
INTRINSIC BIOPROBES, INC., 2155 E. Conference Dr. Suite 104, TEMPE, AZ, 85284
DUNS: 965127038
HUBZone Owned: Y
Woman Owned: N
Socially and Economically Disadvantaged: N
Principal Investigator
 DOBRIN NEDELKOV
 (480) 804-1778
 DNEDELKOV@INTRINSICBIO.COM
Business Contact
 KEMMONS TUBBS
Phone: (480) 804-1778
Email: info@intrinsicbio.com
Research Institution
N/A
Abstract
DESCRIPTION (provided by applicant): The main objective of this Phase I project is to develop quantitative Mass Spectrometric Immunoassays for beta-2-microglobulin, cystatin C, transferrin, transthyretin, and retinol binding protein. These five proteins were recently assayed via qualitative mass spectrometric immunoassays in 1,000 healthy cohorts, detecting (without providing concentration information) numerous protein variant. Because sandwich-based immunoassays such as ELISAs cannot specifically quantify the subtle protein modifications, in this project we propose to develop quantitative mass spectrometric immunoassays for these proteins and their isoforms. An internal reference standard will be carefully chosen, and a step-by-step standard curve quantitative mass spectrometric immunoassay development will be undertaken. The precision (intra-assay and inter-assay), linearity, sensitivity, and specificity of the quantitative mass spectrometric immunoassays will be determined. As a final validation step, the quantitative MSIA assays will be evaluated and benchmarked against existing ELISA assays. The quantitative mass spectrometric immunoassays proposed here will offer unique and straightforward means of quantifying protein variants, and when applied to disease cohorts, can provide valuable insight into the role of these variants in the onset of the disease, progression, and response to therapy. PUBLIC HEALTH RELEVANCE: The development of quantitative Mass Spectrometric Immunoassays for beta-2- microglobulin, cystatin C, transferrin, transthyretin, and retinol binding protein will enable routine quantitative monitoring of these proteins and the changes in their modifications patterns that might be relevant to disease. With the new assays in hand, we will be better equipped to study the effects of these proteins' modifications in pathological processes and evaluate their potential as new indicators of the onset and progression of diseases, and response to therapy.

* Information listed above is at the time of submission. *

Agency Micro-sites

SBA logo
Department of Agriculture logo
Department of Commerce logo
Department of Defense logo
Department of Education logo
Department of Energy logo
Department of Health and Human Services logo
Department of Homeland Security logo
Department of Transportation logo
Environmental Protection Agency logo
National Aeronautics and Space Administration logo
National Science Foundation logo
US Flag An Official Website of the United States Government